ABC-294640
ABC-294640 is in phase I/II clinical trials for the treatment of refractory/relapsed diffuse large B-cell lymphoma (DLBCL).
It is also in phase I clinical trials for the treatment of solid tumors.
The compound was originally developed by Apogee Biotechnology, RedHill Biopharma acquired worldwide rights from Apogee in 2015.
General Information
Update Date：2016-01-04
- Drug Name：
- ABC-294640
- Research Code：
- ABC-294640
- Trade Name：
- MOA：
- Sphingosine kinase 2 (Sphk2) inhibitor
- Indication：
- Solid tumours; B-cell lymphoma
- Status：
- Phase II (Active)
- Company：
- RedHill Biopharma (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-10-10
|
Molecular Weight | 417.37 | ||||||||||||
| Formula | C23H25ClN2O●HCl | |||||||||||||
| CAS No. |
915385-81-8 (ABC 294640); 1185157-59-8 (ABC 294640); |
|||||||||||||
| Chemical Name | Tricyclo[3.3.1.13,7]decane-1-carboxamide, 3-(4-chlorophenyl)-N-(4-pyridinylmethyl)-, hydrochloride (1:1) | |||||||||||||
| ABC 294640 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||